文献检索，用中文搜 PubMed

1

Why are the Therapeutic Drug Monitoring Results of Voriconazole Inconsistent with CYP2C19 Genetic Testing?伏立康唑的治疗药物监测结果为何与CYP2C19基因检测结果不一致？

J Coll Physicians Surg Pak. 2023 May;33(5):598-599. doi: 10.29271/jcpsp.2023.05.598.

2

Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?伏立康唑药代动力学和药效学的人际因素：CYP2C19 基因型是否足以让我们做出临床决策？

Curr Drug Metab. 2018;19(14):1152-1158. doi: 10.2174/1389200219666171227200547.

3

Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?是否到了系统性伏立康唑药物基因组学研究中枢神经系统曲霉病的时候了？

Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00705-18. Print 2018 Sep.

4

Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.治疗药物监测和细胞色素 P450 2C19 基因分型对伏立康唑临床结局的影响：系统评价。

Ann Pharmacother. 2021 Apr;55(4):509-529. doi: 10.1177/1060028020948174. Epub 2020 Aug 8.

5

CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?CYP2C19基因多态性与伏立康唑的治疗药物监测：我们是否已准备好将药物基因组学应用于临床？

Pharmacotherapy. 2014 Jul;34(7):703-18. doi: 10.1002/phar.1400. Epub 2014 Feb 7.

6

Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series.细胞色素P450 2C19基因功能获得性单核苷酸变异（CYP2C19*17）可识别危重症患者伏立康唑治疗浓度不足：病例系列研究

Intensive Care Med. 2015 Nov;41(11):2013-4. doi: 10.1007/s00134-015-4002-z. Epub 2015 Aug 4.

7

Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.细胞色素P450 2C19基因多态性对伏立康唑临床疗效的影响：一项系统评价和荟萃分析

Eur J Clin Pharmacol. 2016 Oct;72(10):1185-1193. doi: 10.1007/s00228-016-2089-y. Epub 2016 Jul 8.

8

Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.CYP2C19 *17/*17基因型与伏立康唑相关鳞状细胞癌风险的关联

JAMA Dermatol. 2016 Jun 1;152(6):719-20. doi: 10.1001/jamadermatol.2016.0351.

9

Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.CYP2C19 基因型和药物相互作用对伏立康唑血药浓度的影响：西班牙一项遗传药理学-药代动力学前瞻性多中心研究。

Pharmacotherapy. 2020 Jan;40(1):17-25. doi: 10.1002/phar.2351.

10

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.临床药物遗传学实施联盟（CPIC） CYP2C19 和伏立康唑治疗指南。

Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18.

Suppr 超能文献

文献检索

文件翻译

深度研究

Suppr 超能文献

伏立康唑的治疗药物监测结果为何与CYP2C19基因检测结果不一致？

Why are the Therapeutic Drug Monitoring Results of Voriconazole Inconsistent with CYP2C19 Genetic Testing?

作者信息

机构信息

出版信息